MEDROL ACETATE (nda012421)- (0.25%,1%)

Generic Name	METHYLPREDNISOLONE ACETATE	Innovator	PHARMACIA AND UPJOHN
Dosage	0.25%,1%
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	Expired	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders 2. Rheumatic Disorders 3. Collagen Diseases 4. Dermatologic Diseases 5. Allergic States 6. Ophthalmic Diseases 7. Respiratory Diseases 8. Hematologic Disorders 9. Neoplastic Diseases 10. Edematous States 11. Gastrointestinal Diseases 12. Nervous System.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
0.25%	**	**	-	-	-
1%	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of MEDROL ACETATE